A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

Cardiac Repolarization Clinical Trial

Official title:
A Randomized, Positive and Placebo-Controlled Trial to Evaluate the Effects of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

Status Terminated

Clinical Trial Summary

This will be a Phase 1, single-center, 2-part study in healthy subjects. Parts 1 and 2 need to be conducted in sequential order.

Clinical Trial Description

Part 1 will enroll up to 3 cohorts of 6 healthy adult subjects to receive a single dose. The total duration of participation from the Screening visit to the follow-up will be up to 7 weeks (up to 45 days). Part 2 of this study will randomize approximately 32 subjects. The total duration of participation from the Screening visit to the follow-up will be up to 8 weeks (up to 55 days). ;

Study Design

Related Conditions & MeSH terms

Cardiac Repolarization

Clinical Trial Details

NCT number	NCT05758818
Study type	Interventional
Source	Rain Oncology Inc
Contact
Status	Terminated
Phase	Phase 1
Start date	April 17, 2023
Completion date	June 8, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01232413` - A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects	Phase 1
Completed	`NCT01819857` - Droperidol and Cardiac Repolarization	Phase 4
Completed	`NCT01487135` - Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects	Phase 1
Completed	`NCT00588965` - Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects	N/A